drugset / Trial / NCT05574036

Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia

NCT05574036

Phase 2 Active not recruiting 70 enrolled Tanta University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims at evaluating and comparing the protective outcomes of using Febuxostat versus Vitamin E in Hyperuricemia non-alcoholic steatohepatitis patients without cirrhosis. The intervention is 6-months duration and the study will assess the efficacy of either drug as fibrosis improvement (≥ 1 stage) with no worsening of NASH or NASH resolution with no worsening of fibrosis with the study considered successful if either 1ry end point is met. Also, assessment of biochemical markers related to steatosis, inflammation, oxidative stress, insulin resistance and liver fibrosis will be done.

Timeline

Start
2022-08-25
Primary completion
2026-05-30
Completion
2026-12-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Febuxostat Small molecule 80 mg Oral
Comparator Vitamin E Unknown 400 mg Oral